Neurocognitive impairment in treatment-experienced adults living with HIV attending primary care clinics in Zimbabwe.
Activities of Daily Living
Adolescent
Adult
Anti-Retroviral Agents
/ adverse effects
Cognitive Dysfunction
/ epidemiology
Executive Function
Female
HIV
HIV Infections
/ complications
Humans
Learning
Male
Middle Aged
Neuropsychological Tests
Prevalence
Primary Health Care
Surveys and Questionnaires
Young Adult
Zimbabwe
/ epidemiology
HIV
Neurocognitive impairment
Neuropsychological assessment
Treatment-experienced
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
29 May 2020
29 May 2020
Historique:
received:
13
01
2020
accepted:
13
05
2020
entrez:
31
5
2020
pubmed:
31
5
2020
medline:
20
6
2020
Statut:
epublish
Résumé
HIV affects the central nervous system resulting in HIV associated neurocognitive impairment (NCI) in approximately 50% of people living with HIV. It typically affects memory, learning, working memory, fine motor skills, speed of information processing, verbal fluency and executive functioning cognitive domains. NCI can affect adherence to antiretroviral therapy (ART), employability, driving ability and activities of daily living. NCI is not routinely screened for in Zimbabwe, and the burden is not known in this setting. The objectives of this study were: 1) To determine NCI prevalence using a comprehensive neuropsychological battery at two primary health care clinics in Harare; 2) To assess the pattern of cognitive impairment across cognitive domains using a gold standard neuropsychological (NP) battery in HIV-positive patients compared to HIV-negative controls. Inclusion criteria: 18 years or older; minimum 7 years education; no neurological or psychiatric disorders. HIV-positive participants were on ART for ≥3 months; HIV-negative participants had a confirmed HIV negative status in the past month. A comprehensive NP battery, functional assessments, demographic and medical history questionnaires were administered. The NP battery consisted of tests assessing memory, learning, working memory, fine motor skills, speed of information processing, verbal fluency and executive functioning. Two-hundred-and-thirty-one participants were recruited. Of those, 155 were HIV-positive (Female = 70%, Age M = 37.8; SD 11.2) and 76 HIV-negative (Female = 63%, Age M = 31.2; SD 9.9). HIV-positive participants were on ART for an average of 6 years. NCI was present in 49.7% HIV positive participants. Compared to HIV-negative participants, the HIV-positive group had significantly poorer scores in 5 out of 7 cognitive domains. A good level of education is negatively correlated with NCI. NCI prevalence in HIV-positive population Zimbabwe is consistent with global estimates. NCI persists in adults who are on ART. Routine assessment of NCI in adults attending primary care clinics using this adapted battery is therefore important so that they are identified early and are provided the necessary interventions.
Sections du résumé
BACKGROUND
BACKGROUND
HIV affects the central nervous system resulting in HIV associated neurocognitive impairment (NCI) in approximately 50% of people living with HIV. It typically affects memory, learning, working memory, fine motor skills, speed of information processing, verbal fluency and executive functioning cognitive domains. NCI can affect adherence to antiretroviral therapy (ART), employability, driving ability and activities of daily living. NCI is not routinely screened for in Zimbabwe, and the burden is not known in this setting. The objectives of this study were: 1) To determine NCI prevalence using a comprehensive neuropsychological battery at two primary health care clinics in Harare; 2) To assess the pattern of cognitive impairment across cognitive domains using a gold standard neuropsychological (NP) battery in HIV-positive patients compared to HIV-negative controls.
METHODS
METHODS
Inclusion criteria: 18 years or older; minimum 7 years education; no neurological or psychiatric disorders. HIV-positive participants were on ART for ≥3 months; HIV-negative participants had a confirmed HIV negative status in the past month. A comprehensive NP battery, functional assessments, demographic and medical history questionnaires were administered. The NP battery consisted of tests assessing memory, learning, working memory, fine motor skills, speed of information processing, verbal fluency and executive functioning.
RESULTS
RESULTS
Two-hundred-and-thirty-one participants were recruited. Of those, 155 were HIV-positive (Female = 70%, Age M = 37.8; SD 11.2) and 76 HIV-negative (Female = 63%, Age M = 31.2; SD 9.9). HIV-positive participants were on ART for an average of 6 years. NCI was present in 49.7% HIV positive participants. Compared to HIV-negative participants, the HIV-positive group had significantly poorer scores in 5 out of 7 cognitive domains. A good level of education is negatively correlated with NCI.
CONCLUSIONS
CONCLUSIONS
NCI prevalence in HIV-positive population Zimbabwe is consistent with global estimates. NCI persists in adults who are on ART. Routine assessment of NCI in adults attending primary care clinics using this adapted battery is therefore important so that they are identified early and are provided the necessary interventions.
Identifiants
pubmed: 32471350
doi: 10.1186/s12879-020-05090-8
pii: 10.1186/s12879-020-05090-8
pmc: PMC7257139
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
383Subventions
Organisme : Wellcome Trust (GB) DELTAS Africa Initiative
ID : 15-01
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Int AIDS Soc. 2013 Jul 23;16:18506
pubmed: 23883539
Percept Mot Skills. 1977 Apr;44(2):367-73
pubmed: 866038
Clin Neuropsychol. 2019 Jan-Dec;33(sup1):1-26
pubmed: 31043112
PLoS One. 2011 Feb 18;6(2):e17233
pubmed: 21365002
AIDS. 2017 Jun 1;31 Suppl 2:S165-S172
pubmed: 28471947
Int Rev Psychiatry. 2008 Feb;20(1):33-47
pubmed: 18240061
Lancet Infect Dis. 2013 Nov;13(11):976-86
pubmed: 24156898
Clin Infect Dis. 2012 Sep;55(6):868-76
pubmed: 22661489
Neuropsychol Rev. 2009 Jun;19(2):232-49
pubmed: 19455425
BMC Infect Dis. 2016 Oct 28;16(1):617
pubmed: 27793128
Appl Neuropsychol Adult. 2020 Mar-Apr;27(2):173-180
pubmed: 30265567
J Neurol. 2017 Aug;264(8):1715-1727
pubmed: 28567537
Curr HIV Res. 2012 Mar;10(2):133-42
pubmed: 22329519
Nat Rev Immunol. 2005 Jan;5(1):69-81
pubmed: 15630430
Nat Rev Neurol. 2016 Apr;12(4):234-48
pubmed: 26965674
Qual Health Res. 2018 May;28(6):859-872
pubmed: 29676675
AIDS Behav. 2017 Jun;21(6):1717-1727
pubmed: 27278547
J Int Neuropsychol Soc. 1999 Nov;5(7):579-92
pubmed: 10645701
Front Immunol. 2016 Sep 30;7:397
pubmed: 27746784
Curr HIV/AIDS Rep. 2015 Mar;12(1):16-24
pubmed: 25604237
J Mol Psychiatry. 2014 Mar 04;2(1):2
pubmed: 25945248
Neurology. 2007 Oct 30;69(18):1789-99
pubmed: 17914061
Clin Infect Dis. 2016 Sep 1;63(5):687-693
pubmed: 27325690
J Neuroimmune Pharmacol. 2007 Mar;2(1):105-11
pubmed: 18040833
Neurology. 2010 Dec 7;75(23):2087-96
pubmed: 21135382
J Int Neuropsychol Soc. 2017 Aug;23(7):605-615
pubmed: 28625210
Curr HIV/AIDS Rep. 2008 Nov;5(4):204-11
pubmed: 18838060
AIDS. 2014 May 15;28(8):1193-202
pubmed: 24556869
Arch Clin Neuropsychol. 1999 Feb;14(2):167-77
pubmed: 14590600
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
J Neurovirol. 2016 Dec;22(6):808-815
pubmed: 27245592
Neuropsychol Rev. 2009 Jun;19(2):152-68
pubmed: 19462243
Medicine (Baltimore). 2016 Apr;95(15):e3361
pubmed: 27082595
PLoS One. 2014 Jun 10;9(6):e98962
pubmed: 24915530
J Neurovirol. 2016 Apr;22(2):170-8
pubmed: 26407716
Neuropsychology. 2018 Jul;32(5):519-528
pubmed: 29504779
BMJ. 2012 Jan 05;344:d7622
pubmed: 22223828